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A NOVEL APPROACH FOR EX-VIVO EXPANSION (EVE) OF NK CD3-/
CD16/56BRIGHT/DIM SUBSETS EXPRESSING INCREASED INHIBITORY
RECEPTORS FROM CRYOPRESERVED/THAWED/EXPANDED/RECRYO-
PRESERVED/RETHAWED (CTECT) AND CRYOPRESERVED/THAWED/RE-
CRYOPRESERVED/RETHAWED/EXPANDED (CTCTE) UMBILICAL CORD
BLOOD (UCB) USING ANTI-CD3, IL-2, IL-7 AND IL-12 (AB/CY)
Ayello, J.1, Satwani, P.1, van de Ven, C.1, Simpson, L.L.1, Kurtzberg,
J.2, Cairo, M.S.1 1. Children’s Hospital of New York-Presbyterian,
Columbia University, New York, NY; 2. Duke University, Durham,
NC
CD56brightdimNK express killer-Ig-like receptors (KIR) and
C-lectin (NKG2), and natural cytoxicity receptors (NCR) involved
with tumor target recognition may play a role in ACI of malig-
nancies (Farag et al, Blood 100:1935, 2002). We compared expan-
sion, maturation and cell survival of CD3-/CD16/56,
CD56bright/dim, KIR inhibitory and C-lectin NK subsets in UCB
aliquots. Non-adherent cells were cultured in SF AIM-V alone or
with anti-CD3 (50 ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml) and
IL-12 (10 ng/ml) (AB/CY). The expanded population was analyzed
for expression of NK subsets (CD94, CD16, CD56bright/dim)
and NK receptors (KIR3DL1, KIR2DL1/S1, KIR2DL2 and
NKG2A) by ﬂow cytometry using CD16, CD56, NKBL1,
CD158a, CD158b, CD94 and NKG2A mAbs. Apoptotic markers
were determined by presence of Annexin V and PI. A signiﬁcant
increase in CD16/CD56bright /dim  and CD94/NKG2A ex-
pression was seen in CTECT and CTCTE in AB/CY compared to
AIM-V alone (CD16/56bright/CTECT: 11 1 vs 2.5 .3%, p
.05; CD16/CD56dim: 46  6 vs 27  2%, p  .03; CD16/
56bright/CTCTE: 9  2 vs 2  .2%, p  .05; CD16/CD56dim:
40  2 vs 27  3%, p  .01; CD94/NKG2A: CTECT: 17  3
vs 2  .9%, p  .001; CTCTE: 25  2 vs 8  3%, p  .001).
Signiﬁcant increases were seen in NK KIR receptors expression
(CD56bright/KIR3DL1 and CD56dim/KIR3DL1) when AB/CY
was compared to AIM-V (CTECT: 11  0.7 vs .4  .07%, p 
.0001; 4  0.1 vs 1.5  0.4%, p  .003; CTCTE: 7  2 vs 1  .3
%, p  .05; 8  1 vs 3  .8%, p  .01, respectively), CD56bright/
KIR2DL1/S1 and CD56dim/KIR2DL1/S1 (CTECT: 12  1 vs
3  .4%, p  .004; 41  2 vs 9  1%, p  .0002; CTCTE: 6 
.5 vs 2  .1%, p  .05; 22  8 vs 5  1, p  .01) and CD56bright/
KIR2DL2 and CD56dim/KIR2DL2 (CTECT: 14  .8 vs 2 
.2%, p  .0002 and 29  .9 vs 12  .4%, p  .0001; CTCTE:
14  2 vs 2  .1%, p  .05 and 25  7 vs 6  1%, p  .001,
respectively). To determine if the increase was secondary to in-
creased cell survival, CTECT and CTCTE AB/CY expanded
cultures showed minimal apoptosis compared to SF AIM-V (1.1 
3 vs 6 .5%, p .001; 5 1 vs 11 .6%, p .05). No signiﬁcant
difference between CTECT and CTCTE modalities was seen
except in CD94/NKG2A (p  .05) and CD56bright/KIR2DL2
(p  .05). These data suggest that CD16/CD56bright/dim NK
subsets expressing increased KIR and C-lectin receptors can be
EvE with AB/CY from CTECT or CTCTE UCB for possible use
in ACI for DLI after UCBT. In-vitro functional and in-vivo
xenotransplant animal studies are underway to further examine the
cytolytic activity of these UCB NK subsets.
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EX VIVO EXPANSION OF IMMATURE AND MATURE T CELLS DERIVED
FROM UMBILICAL CORD BLOOD (UCB)
Staba, S.L., Crapnell, K.B., Hall, J.G., Reese, M., Kurtzberg, J. Duke
University Medical Center, Durham, NC
Introduction: Unrelated umbilical cord blood (UCB) is an effec-
tive source of allogeneic hematopoietic stem cells for transplanta-
tion therapy in patients lacking matched bone marrow donors.
Opportunistic infection is the major cause of mortality post trans-
plant, due in part to the immunologic naivete´ of the UCB T-cells.
We hypothesized that UCB derived immature and mature T-cells
could be expanded ex-vivo, and utilized a patient-derived skin
stromal layer with a supplemental cytokine cocktail to support the
growth of bulk UCB cells. The long term goal is to provide
UCB-derived adoptive immunotherapy in UCBT recipients.
Methods: Patient derived skin ﬁbroblasts were cultured in a media
of IMDM, 10% fetal calf serum and 10% horse serum for 14 days,
then irradiated to 5,000 cGy. Cryopreserved UCB cells were
thawed and cultured on this stromal layer in the same media
supplemented with a cytokine cocktail of interleukin-7 (IL-7) (10
ng/ml), ﬂt-3 ligand (10 ng/ml), and stem cell factor (50 ng/ml).
UCB cells were cultured with cytokines alone and skin alone as
controls. As a 2nd phase, interleukin-2 (IL-2) was added at day 14
for further expansion, with cells cultured for an additional 14 days
thereafter. Cell count, viability, and FACs analysis were per-
formed. Results: Gating on CD3, in cells cultured with both
skin stroma and cytokines mean fold increases of 6 in CD4, 11 in
CD8 and 34 in CD4/CD8 cells were seen. With cytokines
alone, mean fold increases were 3, 4 and 10 respectively. Minimal
expansion occurred with skin alone. With cytokines and IL-2,
mean fold increases were 4 in CD4, 4 in CD8 and 10 in
CD4/CD8 cells. Maximal expansion occurred with skin
stroma, the cytokine cocktail and IL-2, with mean fold increases of
9 in CD4, 11 in CD8 and 53 in CD4/CD8 cells. Results are
summarized in the table below. Conclusions: The expansion of
T-cells from unfractionated, red blood cell depleted, cryopreserved
UCB can be accomplished using a cytokine cocktail of IL-7, Flt 3
ligand and SCF over a patient derived, irradiated skin stromal
layer. Maximal expansion occurs with the addition of IL-2 and was
greatest in the immature CD4/CD8T-cell subset. We hypoth-
esize that this subset of T cells could serve as a target population
for adoptive immunotherapy, however further testing will deter-
mine the optimal cellular target and conditions for ex vivo expan-
sion and immunization. These cells could then be used to augment
immune reconstitution after UCBT.
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ISOLATION AND FUNCTIONAL INHIBITORY AFFECTS OF SPECIFIC PEP-
TIDES BOUND TO TYPE 2 DENDRITIC CELLS (DC2)
Rosenthal, H.S., Jaye, D.L., Cherry, E., Waller, E.K. Emory Univer-
sity, Atlanta, GA
Introduction: The impact of immunoregulatory type 1 (DC1)
and type 2 (DC2) dendritic cells in allogeneic hematopoetic pro-
genitor cell (HPC) transplantation has increased in interest. We
have shown that greater numbers of DC2s in allogeneic HPC
transplanted grafts has resulted in an increase in post-transplant
relapse and a reduction of graft vs host disease (GVHD). Isolation
of dendritic cell speciﬁc peptides thru phage display technology
provides a method of studying the immunoregulatory affects of
these cells and perhaps engineer grafts with anti-tumor affects.
Method: Random phage peptide libraries were incubated over-
night at 4° C with column enriched peripheral blood DC2 cells.
Unbound phage was removed by washing. FACS sorting of the
Lin-, CD123, HLA-Dr cells, further puriﬁed the DC2 popu-
lation. DC2 bound phage were removed from the cell surface,
eluted and puriﬁed. Three rounds of this phage selection process
(panning) were performed. A portion of the round 2 phage puri-
ﬁcation was incubated with enriched monocytes prior to incuba-
tion with DC2 cells to assist in eliminating phage that recognized
common epitopes on both cell types. Flow cytometry identiﬁed





Skin Alone (n  8) 0 0 0
Cytokines (n  10) 3 4 10
Cytokines  IL-2 (n  5) 4 4 10
Skin  Cytokines (n  10) 6 11 34
Skin  Cytokines  IL-2 (n  5) 9 12 53
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highly DC2 selective. Selective clones were DNA sequenced re-
vealing the random peptide insert. A 1-way MLR was performed
with varying dilution of each ampliﬁed DC2 speciﬁc phage to
demonstrate the cellular affects on allogeneic T-cell proliferation.
Results: Plaque assays from the monocyte adsorbed or non-ad-
sorbed linear random peptide library after the three rounds of
panning revealed two consensus sequences in 76 of the 78 (97%)
isolated clones that were DC2 selective and one sequence found
twice (3%) that was non-DC2 selective. The employed circular
random peptide library revealed no DC2 selective sequences from
15 isolated in clones from the monocyte adsorbed and non-ad-
sorbed plaque assays. Preliminary MLR data shows a 35 % reduc-
tion in allogeneic T-cell proliferation with the DC2 speciﬁc phage
compared to control phage. Conclusions: Data shows that phage
display technology can result in isolating highly speciﬁc DC2
peptides from a library of 10,000 different phage clones. Prelimi-
nary data suggests that binding DC2 speciﬁc peptides may inhibit
the function of these immunoregulatory cells, leading to enhanced
anti-tumor affect of the transplanted donor graft product by shift-
ing it towards an activated Th1 immune response.
GVH/GVL
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TREATMENT WITH GRANULOCYTE COLONY-STIMULATING FACTOR
AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION FOR ACUTE
LEUKEMIA INCREASES THE RISK OF GRAFT-VERSUS-HOST DISEASE
AND DEATH
Ringde´n, O.1, Labopin, M.2, Gorin, N.C.2, Le Blanc, K.1, Rocha, V.3,
Gluckman, E.3, Reiffers, J.4, Arcese, W.5, Vossen, J.M.6, Jouet, J.-P.7,
Cordonnier, C.8, Frassoni, F.9 1. Centre for Allogeneic Stem Cell Trans-
plantation and Division of Clinical Immunology, Huddinge Univ. Hos-
pital, Stockholm, Sweden; 2. Hopital Saint-Antoine and EBMT Data
Center, Institut des Cordeliers, Paris, France; 3. Hopital Saint-Louis,
Paris, France; 4. GRP Hopital de Haut-Leve`que, Pessac, France; 5.
University La Sapienza, Rome, Italy; 6. BMT Centre, Leiden University
Hospital, Leiden, Netherlands; 7. Service des Maladies du Sang, Hospital
Claude Huriez, Lille, France; 8. Hospital Henri Mondor, Creteil,
France; 9. Ospedale San Martino, Genova, Italy
Purpose: Granulocyte colony-stimulating factor (G-CSF) is
given after bone marrow transplantation (BMT) to shorten the
neutropenic phase. Its effects have not been evaluated in a large
patient population. Patients and Methods: We studied 1789 pa-
tients with acute leukaemia receiving BMT and 434 patients re-
ceiving peripheral blood stem cells (PBSC) from HLA-identical
siblings from 1992 to 2002 and reported the ﬁndings to the Eu-
ropean Group for Blood and Marrow Transplantation (EBMT).
Among the BMT and PBSC patients, 501 (28%) and 175 (40%),
respectively, were treated with G-CSF during the ﬁrst 14 days after
the transplant. The outcome variables were entered in a Cox
proportional hazard model. Results: BMT and PBSC patients
treated with G-CSF had a faster engraftment of absolute neutro-
phils 0.5  109/l (p  0.01), but platelet engraftment (50 
109/l) was slower (p  0.001). In the BMT patients, acute graft-
versus-host disease (GVHD) grades II-IV was 50  5% (95%
conﬁdence interval) in the G-CSF group vs. 39  3% in the
controls (relative risk (RR) 1.33, p  0.007, in the multivariate
analysis). The incidence of chronic GVHD was also increased (RR
0.29, p  0.03).
G-CSF was associated with an increase in transplant-related
mortality (TRM) (RR 1.73, p  0.00016), had no effect on relapse,
but reduced the survival (RR 1.7, p  0.0001) and leukaemia-free
survival rates (LFS) (RR 1.55, p  0.0003). No such effects of
G-CSF were seen in patients receiving PBSC. Conclusion: After
BMT, platelet engraftment was delayed, and GVHD and TRM
were increased. Survival and LFS were reduced. This suggests that
G-CSF should not be given shortly after BMT.
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SUBEROYLANILIDE HYDROXAMIC ACID REDUCES ACUTE GRAFT-VER-
SUS-HOST DISEASE AND PRESERVES GRAFT-VERSUS-LEUKEMIA EF-
FECT BY INHIBITING HISTONE DEACETYLATION
Reddy, P.1, Maeda, Y.1, Hotary, K.1, Dinarello, C.A.2, Ferrara, J.L.1 1.
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;
2. University of Colorado Medical Center, Denver, CO
Pro-inﬂammatory cytokines and the loss of gastrointestinal tract
integrity contribute to acute graft-versus-host disease (GVHD)
whereas the donor cytotoxic responses are critical for graft-versus-
leukemia (GVL) preservation. Suberoylanilide hydroxamic acid
(SAHA) is an anti-tumor agent that inhibits the activity of histone
deacetylases (HDAC) and reduces the production of proinﬂamma-
tory cytokines. Using a well characterized allogeneic murine BMT
model B6 (H-2b) 3 B6D2F1 (H-2b/d) we studied the effects of
HDAC inhibition by SAHA on acute GVHD. Recipients were
transplanted with 2x10 6 donor T and 5x106 BM cells after13 GY
TBI. Intra-peritoneal injections of 35 mg/kg/day of SAHA from
days 3 to day 7 increased histone H3 acetylation in splenocytes
harvested 7 days after BMT, conﬁrming the inhibition of HDAC
enzymes. SAHA treatment signiﬁcantly reduced the serum levels of
pro-inﬂammatory cytokines such as TNF-a, IL-1	 and IFN-

(P  0.04) in the allogeneic recipients on day 7 after BMT.
Intracytoplasmic staining by ﬂow cytometry and RPA analysis of
the host splenocytes on day 7 conﬁrmed the decrease in the
cytokine protein and mRNA. SAHA signiﬁcantly improved the
survival (P 0.002) and reduced intestinal damage from GVHD of
the allogeneic recipients . However SAHA did not suppress the
donor T cell expansion in vivo and the proliferative and cytotoxic
responses to host antigens in vitro measured 7 and 14 days after
BMT. To test the effect of SAHA on GVL effects, recipients were
injected with lethal doses of P815 (H-2d) tumor cells at the time of
BMT. SAHA treatment resulted in signiﬁcantly improved leuke-
mia-free survival after allogeneic BMT (P  0.05) whereas all the
syngeneic BMT recipients of SAHA died of tumor ruling out
direct anti-tumor effects of SAHA. Furthermore SAHA increased
H3 acetylation in the splenocytes from both the syngeneic and
allogeneic leukemic recipients on day 7, conﬁrming that inhibi-
tion of HDAC enzymes alone is not sufﬁcient for leukemia free
survival in this system. We also tested the effect of SAHA in a
second allogeneic BMT model (BALB/c 3 B6), where it also
signiﬁcantly improved survival (P  0.001) and preserved GVL
effects when recipient mice were injected with lethal doses of EL-4
(H-2b) tumor (P  0.04). We conclude that HDAC inhibition
regulates acute GVHD in these models and suggest that this class
of pharmacologic agents may provide a novel strategy to reduce
GVHD while maintaining the beneﬁcial GVL effects.
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ABROGATION OF THE INTERACTIONS BETWEEN CXCR3 AND ITS LI-
GANDS MIG AND IP-10 REDUCES THE SEVERITY OF IDIOPATHIC PNEU-
MONIA SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
TION
Hildebrandt, G.C.1, Corrion, L.C.1, Olkiewicz, K.M.1, Liu, C.2, Cooke,
K.R.1 1. Dept. of Pediatrics; BMT Program, University of Michigan,
Ann Arbor, MI; 2. Dept. of Pathology; University of Florida School of
Medicine, Gainesville, FL
Chemokines are important mediators in the development of
Idiopathic Pneumonia Syndrome (IPS), a major cause of mortality
after allogeneic (allo) stem cell transplantation (SCT). We hypoth-
esized, that recruitment of donor T cells to the lung is dependent,
at least in part, upon interactions between the chemokines MIG
and IP-10 and their receptor CXCR3. CXCR3 is expressed on
activated T cells; MIG and IP-10 can be induced in various cell
types by IFN
 alone or in combination with TNFa or IL-1ß. We
tested this hypothesis using an established murine SCT model
wherein lethally irradiated bm1 mice receive SCT from either
syngeneic (bm1) or allogeneic (B6Ly5.2) donors. MIG and IP-10
BAL levels were signiﬁcantly elevated in allo recipients compared
to syn controls at weeks 1 (MIG: 162.8  37.6 vs 0; IP-10: 41.1 
4.2 vs 0 pg/ml) and 4 (MIG: 153.5  41.7 vs 21.6  9.0; IP-10:
202.0  61.1 vs 3.8  0.9 pg/ml) and correlated with the inﬁltra-
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